Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The FIND Study: A Dose-finding Study to Identify the Optimal Dose of Zanubrutinib in Adults With Immune Thrombocytopenia

NCT07315373 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07315373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07315373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The FIND Study: A Dose-finding Study to Identify the Optimal Dose of Zanubrutinib in Adults With Immune Thrombocytopenia
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 25, 2025
Completion date
June 30, 2029
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia